

*Amendments to the Claims*

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-7 (Cancelled).

Claim 8 (Currently amended): A purified protein ~~comprising~~ consisting of at least a polypeptide sequence of 30 contiguous amino acids of SEQ ID NO:2, wherein said protein has a biological activity selected from the group consisting of:

- (a) ~~binding an antibody specific to the polypeptide of SEQ ID NO:2;~~
- (b) ~~inducing apoptosis of a cell line derived from pathologic tissue; and~~
- (c) ~~inducing apoptosis of T cells.~~

Claim 9 (Currently amended): The purified protein of claim 8 ~~which comprises~~ consisting of at least a polypeptide sequence of 50 contiguous amino acids of SEQ ID NO:2.

Claim 10 (Currently amended): A purified protein consisting of ~~comprising~~ a polypeptide sequence that is a fragment of amino acids 1 to 281 of SEQ ID NO:2, wherein said polypeptide sequence has a biological activity selected from the group consisting of:

- (a) producing ~~binding~~ an antibody specific to the polypeptide of SEQ ID NO:2;
- (b) inducing apoptosis of a cell line derived from pathologic tissue; and
- (c) inducing apoptosis of T cells.

Claim 11 (Cancelled).

Claim 12 (Original): A composition comprising the purified protein of claim 10 and a pharmaceutically acceptable carrier.

Claim 13 (Original): A purified protein comprising a polypeptide sequence selected from the group consisting of:

- (a) the amino acid sequence of the full-length polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97448; and
- (b) the amino acid sequence of the mature polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97448.

Claim 14 (Original): The purified protein of claim 13, wherein said polypeptide sequence is (a).

Claim 15 (Original): The purified protein of claim 13, wherein said polypeptide sequence is (b).

Claim 16 (Cancelled).

Claim 17 (Original): A composition comprising the purified protein of claim 13 and a pharmaceutically acceptable carrier.

Claims 18-24 (Cancelled).

Claim 25 (Currently amended): A purified protein produced by a process comprising: expressing in a host cell a nucleic acid encoding said protein so as to produce said protein, wherein the nucleic acid is selected from the group consisting of:

- (a) a polynucleotide encoding amino acids 1 to 281 of SEQ ID NO:2;
- (b) a polynucleotide encoding amino acids 39 to 281 of SEQ ID NO: 2; and

~~(c) a polynucleotide encoding amino acids 1 to 281 of SEQ ID NO:2, except for 1 to 5 conservative amino acid substitutions;~~

~~(d) a polynucleotide encoding amino acids 1 to 281 of SEQ ID NO:2, except for 5 to 10 conservative amino acid substitutions;~~

~~(e) a polynucleotide encoding amino acids 39 to 281 of SEQ ID NO:2, except for 1 to 5 conservative amino acid substitutions;~~

~~(f) a polynucleotide encoding amino acids 39 to 281 of SEQ ID NO:2, except for 5 to 10 conservative amino acid substitutions;~~

~~(c) (g) a polynucleotide encoding the amino acid sequence encoded by the human cDNA contained in ATCC Deposit No. 97448;~~ and

~~(h) a polynucleotide that is complementary to a polynucleotide which hybridizes at 60°C in a hybridization buffer consisting of 0.5 X SSC and 0.1% SDS to a polynucleotide selected from the group consisting of:~~

~~(i) a polynucleotide encoding amino acids 1 to 281 of SEQ ID NO:2;~~

~~(ii) a polynucleotide encoding amino acids 39 to 281 of SEQ ID NO: 2; and~~

~~(iii) a polynucleotide encoding the amino acid sequence encoded by the human cDNA contained in ATCC Deposit No. 97448;~~

~~wherein said polynucleotide encodes a polypeptide that has a biological activity selected from the group consisting of:~~

~~(aa) producing binding an antibody specific to the polypeptide of SEQ ID NO:2;~~

~~(bb) inducing apoptosis of a cell line derived from pathologic tissue; and~~

~~(cc) inducing apoptosis of T cells.~~

Claim 26 (Cancelled).

Claim 27 (Original): A composition comprising the purified protein of claim 25 and a pharmaceutically acceptable carrier.

Claims 28-29 (Cancelled).

Claim 30 (New): A purified protein comprising a polypeptide selected from the group consisting of:

- (a) amino acids 1 to 281 of SEQ ID NO:2; and
- (b) amino acids 39 to 281 of SEQ ID NO:2.

Claim 31 (New): The purified protein of claim 30, wherein said polypeptide, sequence is (a).

Claim 32 (New): The purified protein of claim 30, wherein said polypeptide sequence is (b).

Claim 33 (New): A composition comprising the purified protein of claim 30 and a pharmaceutically acceptable carrier.

Claim 34 (New): A purified protein consisting of at least 30 contiguous amino acids of SEQ ID NO:2, fused to a heterologous polypeptide.

Claim 35 (New): The protein of claim 34, wherein said protein consists of at least 50 contiguous amino acids of SEQ ID NO:2, fused to a heterologous polypeptide.

Claim 36 (New): A composition comprising the purified protein of claim 34 and a pharmaceutically acceptable carrier.

Claim 37 (New): The protein of claim 25, wherein said host cell is a eukaryotic cell.

Claim 38 (New): A composition comprising the purified protein of claim 8 and a pharmaceutically acceptable carrier.